Our Technology

Our proprietary autologous fibroblast technology is the foundation for creating personalized biologics for rare disease of the skin and connective tissue.

One Platform Drives Multiple Product Engines

autologous fibroblast and gene therapy engines

Lorem ipsum dolor sit amet, consectetur adipiscing elit sed temp

We have unique, proven capabilities with autologous fibroblast cells—the most common cell in skin and connective tissue. Using this proprietary technology offers us significant opportunities to develop cell and gene therapies that target the underlying cause of debilitating rare skin and connective tissue diseases.”

— John Maslowski, Senior Vice President, Scientific Affairs